IP Library Granted Patent US 7,842,290
Granted Patent B2
US 7,842,290 · App. 11/840,903 · Granted Nov 30, 2010

Identification of genes

Assignee: Emergent Product Development UK Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,842,290
App. No.
11/840,903
Granted
Nov 30, 2010
Kind
B2
Abstract

A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of: (1) providing a plurality of microorganisms each of which is independently mutated by the insertional inactivation of a gene with a nucleic acid comprising a unique marker sequence so that each mutant contains a different marker sequence, or clones of the said microorganism; (2) providing individually a stored sample of each mutant produced by step (1) and providing individually stored nucleic acid comprising the unique marker sequence from each individual mutant; (3) introducing a plurality of mutants produced by step (1) into the said particular environment and allowing those microorganisms which are able to do so to grow in the said environment; (4) retrieving microorganisms from the said environment or a selected part thereof and isolating the nucleic acid from the retrieved microorganisms; (5) comparing any marker sequences in the nucleic acid isolated in step (4) to the unique marker sequence of each individual mutant stored as in step (2); and (6) selecting an individual mutant which does not contain any of the marker sequences as isolated in step (4).

Claims (16)

1. A modified Salmonella bacterium comprising a mutation in chromosomal DNA located between the ydhE and pkyF genes of the Salmonella chromosome, wherein the mutation attenuates virulence of the Salmonella bacterium when administered to an animal.

2. The modified Salmonella bacterium of claim 1 , wherein the mutation is located in chromosomal DNA normally comprising at least 85% identity to one of SEQ ID NO: 8-11, 14-21, 24-29, 31-35 or 37-38 or fragment thereof, wherein the fragment comprises at least 50 nucleotides.

3. The modified Salmonella bacterium of claim 2 , wherein the fragment comprises at least 100 nucleotides.

4. The modified Salmonella bacterium of claim 1 , wherein the mutation is located in chromosomal DNA normally comprising at least 95% identity to one of SEQ ID NO: 8-11, 14-21, 24-29, 31-35 or 37-38 or a fragment thereof, wherein the fragment comprises at least 100 nucleotides.

5. The modified Salmonella bacterium of claim 1 , wherein the mutation is located in chromosomal DNA normally comprising a nucleic acid sequence of SEQ ID NO: 37 or variant of SEQ ID NO: 37.

6. The modified Salmonella bacterium of claim 1 , wherein the mutation is in a gene component of a type III secretion system.

7. The modified Salmonella bacterium of claim 1 , wherein the Salmonella bacterium is selected from the group consisting of Salmonella enterica, Salmonella typhi , Salmonella typhimurium, Salmonella aberdeen, Salmonella gallinarum and Salmonella cubana.

8. The modified Salmonella bacterium of claim 1 , wherein the mutation is a frameshift or deletion mutation.

9. The modified Salmonella bacterium of claim 1 , wherein the bacterium further comprises DNA encoding an antigenic epitope of another pathogen.

10. A pharmaceutical composition comprising:

a modified Salmonella bacterium, wherein the modified Salmonella bacterium

comprises an attenuating mutation in chromosomal DNA located between the ydhE and

pykF genes of the Salmonella chromosome; and

a pharmaceutical acceptable carrier.

11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition further comprises an adjuvant.

12. The pharmaceutical composition of claim 10 , wherein the Salmonella bacterium further comprises DNA encoding an antigenic epitope from another pathogen.

Assignments (7)
ASSET PURCHASE AGREEMENT Recorded Jan 9, 2013
From: EMERGENT PRODUCT DEVELOPMENT UK LIMITED
To: PROKARIUM LIMITED
Reel/Frame 029595/0644 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2008
From: HOLDEN, DAVID WILLIAM
To: RPMS TECHNOLOGY LIMITED
Reel/Frame 021310/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2008
From: IMPERIAL INNOVATIONS LIMITED
To: EMERGENT PRODUCT DEVELOPMENT UK LIMITED
Reel/Frame 021310/0477 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2008
From: RPMS TECHNOLOGY LIMITED
To: IMPERIAL COLLEGE INNOVATIONS LIMITED
Reel/Frame 021310/0468 →
CHANGE OF NAME Recorded Jul 30, 2008
From: IMPERIAL COLLEGE INNOVATIONS LIMITED
To: IMPERIAL INNOVATIONS LIMITED
Reel/Frame 021310/0509 →
CHANGE OF NAME Recorded Jul 30, 2008
From: MICROSCIENCE LIMITED
To: EMERGENT PRODUCT DEVELOPMENT UK LIMITED
Reel/Frame 021314/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2008
From: IMPERIAL COLLEGE INNOVATIONS LIMITED
To: IMPERIAL COLLEGE INNOVATIONS LIMITED; MICROSCIENCE LIMITED
Reel/Frame 021310/0502 →
Priority Claims (3)
GB 9424921.6 · Dec 9, 1994 · national
GB 9501881.8 · Jan 31, 1995 · national
GB 9509239.1 · May 5, 1995 · national
Continuity (5)
Continuation 1119985300 · Aug 9, 2005
Division 0971460200 · Nov 16, 2000
Continuation 0920194500 · Dec 1, 1998
Continuation 0863775900
Related Publication 20080175866A1 · Jul 24, 2008